Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022

Rhea-AI Summary

Immunovant, Inc. (Nasdaq: IMVT) will release its fourth quarter and full-year 2022 financial results on June 8, 2022, before U.S. market open. The company will also host a conference call and webcast at 8:00 AM ET the same day, featuring a question-and-answer session for investors. Immunovant focuses on therapies for autoimmune diseases, particularly its investigational compound, batoclimab, a monoclonal antibody targeting the neonatal Fc receptor (FcRn). This information can be accessed via their investor relations website.

Positive

• Company will provide financial results on June 8, 2022, indicating transparency and engagement with investors.
• Focus on innovative therapies for autoimmune diseases may attract investor interest.

Negative

• None.

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it will report its fourth quarter and full-year 2022 financial results before the open of the U.S. financial markets on Wednesday, June 8, 2022. The company also plans to host a webcast and conference call on Wednesday, June 8, 2022 at 8:00 AM ET.

Following prepared remarks, the call will include a live question-and-answer session for the investment community. To access the webcast and the presentation being shared on the call, please visit Immunovant’s website at https://www.immunovant.com/investors/news-events.

Participants may also dial in using the numbers provided below:
Toll Free: 1-877-407-9039
Toll/International: 1-201-689-8470

An archived recording of the webcast will be available on Immunovant’s website for a limited time following its conclusion.

About Immunovant, Inc. 

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, we are boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. Our investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com.

Contact:
Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com

FAQ

When will Immunovant report its Q4 and full-year 2022 financial results?

Immunovant will report its Q4 and full-year 2022 financial results on June 8, 2022.

What time is the Immunovant conference call scheduled for?

The conference call is scheduled for 8:00 AM ET on June 8, 2022.

How can I access Immunovant's webcast for financial results?

You can access the webcast for Immunovant's financial results through their investor relations website.

What is batoclimab developed by Immunovant?

Batoclimab is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn) for treating autoimmune diseases.